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Abstract
Background: The Holuhraun volcanic eruption September 2014 to February 2015 emitted large amounts of sulfur
dioxide (SO2). The aim of this study was to determine the association between volcanic SO2 gases on general
population respiratory health some 250 km from the eruption site, in the Icelandic capital area.
Methods: Respiratory health outcomes were: asthma medication dispensing (AMD) from the Icelandic Medicines
Register, medical doctor consultations in primary care (PCMD) and hospital emergency department visits (HED) in
Reykjavík (population: 215000) for respiratory disease from 1 January 2010 to 31 December 2014. The associations
between daily counts of health events and daily mean SO2 concentration and high SO2 levels (24-h mean SO2 >
125 μg/m3) were analysed using generalized additive models.
Results: After the eruption began, AMD was higher than before (129.4 vs. 158.4 individuals per day, p < 0.05). For
PCMD and HED, there were no significant differences between the number of daily events before and after the
eruption (142.2 vs 144.8 and 18.3 vs 17.5, respectively). In regression analysis adjusted for other pollutants, SO2 was
associated with estimated increases in AMD by 0.99% (95% CI 0.39–1.58%) per 10 μg/m3 at lag 0–2, in PCMD for
respiratory causes 1.26% (95% CI 0.72–1.80%) per 10 μg/m3 SO2 at lag 0–2, and in HED by 1.02% (95% CI 0.02–
2.03%) per 10 μg/m3 SO2 at lag 0–2. For days over the health limit, the estimated increases were 10.9% (95% CI 2.1–
19.6%), 17.2% (95% CI 10.0–24.4%) for AMD and PCMD. Dispensing of short-acting medication increased
significantly by 1.09% (95% CI 0.49–1.70%), and PCMD for respiratory infections and asthma and COPD diagnoses
and increased significantly by 1.12% (95% CI 0.54–1.71%) and 2.08% (1.13–3.04%).
Conclusion: High levels of volcanic SO2 are associated with increases in dispensing of AMD, and health care
utilization in primary and tertiary care. Individuals with prevalent respiratory disease may be particularly susceptible.
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Introduction
SO2 (Sulphur dioxide) exposure is associated with
respiratory health morbidity and mortality [1, 2] and at
higher concentrations (a 10 min mean over 500 μg SO2
per m3) it is associated with irritation of the respiratory
tract in susceptible individuals [2] and can trigger
respiratory symptoms such as acute bronchial asthma,
pulmonary oedema, and respiratory distress [3] – espe-
cially in individuals with hyper-reactivity syndrome [4].
Populations within 100 km of a volcanic eruption have
traditionally been considered at risk [5] although studies
have found possible health effects of volcanic ash at
greater distances [6].
During the Holuhraun volcanic eruption in the
Barðarbunga central volcanic system SO2 was dispersed
widely over Iceland according to meteorological condi-
tions [7], reaching the capital area some 250 km from the
eruption site where the 24-h air quality guideline limit for
SO2, 125 μg/m
3 [2], was exceeded repeatedly during the
fall of 2014. The Barðarbunga volcanic system is located
in the central highlands of Iceland which is uninhabited
and no humans live within 50 km of the eruption site so
although there was no immediate danger, several steps
were taken to inform and advise the public of the situation
with the dispersed SO2 gas. Press briefings and commu-
nity meetings were held from mid-September and the civil
protection agency issued warnings by text messages to all
cell phones in the affected areas when high levels of SO2
were expected. During the eruption, there were no formal
disruptions to daily life such as school closings [8].
The eruption in the fall and winter of 2014–2015 was
the largest eruption in Iceland since the Laki eruption in
1783–1784. Some 12 million tons of sulphur dioxide,
SO2, was emitted from the eruption and the resulting
lava field [9], A clinical study of professionals working at
the eruption site with very high exposures found no
serious health effects associated with exposure, perhaps
because they were wearing protective equipment, most
importantly, masks [10].
Exposure to SO2 from active volcanoes is associated
with increased rates of chronic cough and phlegm, as
well dry and sore throat [11–18]. although few fatalities
have been reported from very high SO2 exposure near
active volcanoes [19]. In Hawai’i, PM2.5 (particle matter
with an aerodynamic diameter < 2.5 μm) with a signifi-
cant amount of volcanic emissions was associated with
increased respiratory admissions [20].
While concentration-response relationships between
volcanic SO2 and respiratory symptoms, many of the
studies´ designs and methods leave them prone to bias.
For example, symptoms are often self-reported, or
participants were aware of their exposure status [21],
whereas other studies suffer from a lack of data [22].
Moreover, most of the existing literature pertains to
long-term area-wide exposure whereas SO2 exposure in
Iceland during the Holuhraun eruption was intermittent
with few hours or days of high SO2 concentrations
followed by periods of low SO2 concentrations as wind
directions changed [7]. With population-based registers
on medicine dispensing and health care utilization as
well as vigorous air pollution monitoring in the capital
area, Iceland provides an ideal setting for studying popu-
lation health effects of short-term exposure to SO2 from
a volcanic eruption.
The objective of this study was to study the acute ef-
fects of exposure to SO2 concentrations from a volcanic
source and SO2 concentrations above the air quality
guideline value of 24 h mean of 125 μg/m3) on respira-
tory health in the general population and to investigate
risk differences in subgroups of the population and sus-
ceptible groups.
Material and methods
The Holuhraun volcanic eruption in North-East central
Iceland began 31 August 2014 and ended 27 February
2015. The study period was 1 January 2010–31 December
2014, and the time before the eruption was used a reference
period. The Holuhraun eruption persisted until end of
February 2015, whereas our study period ends 31
December 2014 due to a change in the database
recording of events. However, SO2 never exceeded
the 24-h air quality guideline limit during January
and February 2015, although daily mean concentra-
tions were still higher than before the eruption.
The mean population of Iceland during the study
period was 320,000 inhabitants. The capital area, Reykjavík
and surrounding municipalities, had 205,282 residents at
the beginning of the study period, and 215,965 residents at
the end [23]. The analysis was restricted to the capital area
(residential postcodes 101–171, 200–225, and 270) where
adequate information about SO2 exposure was available for
the whole study period. The Icelandic health care system is
state-centred, mainly publicly funded system with universal
coverage [24]. We obtained data on respiratory health and
individual data on residence (postcode), age, sex and an
anonymous personal identification number from 1)) the
National Medicines Register; 2) Primary care centres (that
function as first point of contact) and 3) Landspitali, the
national university hospital, the country’s centre of clinical
excellence [2]. All registers are held by the Icelandic Direct-
orate of Health and extraction is subject to approval from
the Icelandic Bioethical Committee. From the National
Medicines Register we extracted data on dispensing
(pharmacy sales to individuals) of prescription anti-
asthma medication (AMD) classified by The World
Health Organisation Anatomical Therapeutic Chemical
code R03. AMD relieve symptoms of asthma and
chronic obstructive pulmonary disease, COPD, and are
Carlsen et al. Environmental Health           (2021) 20:23 Page 2 of 12
occasionally prescribed to individuals with respiratory
infections. Furthermore, AMD is a proxy for respiratory
health in a population [25–29]. From the primary care
centers (PCC) and hospital emergency department
(HED) databases at the Directorate of Health we ex-
tracted data on individuals diagnosed with respiratory
illnesses.
In the main analyses, we analysed the number of MD
visits in primary care (PCMD) and all HED visits regard-
less of admission status. As the same bout of illness is
likely to result in recurring contacts with the health care
system, we included only the first record of an individ-
ual’s health care contacts within a 14-day period for the
same diagnosis category to avoid exposure misclassifica-
tion with respect to the timing of the outcome. For each
outcome, we constructed daily time series starting 1
January 2010 to 31 December 2014 for the following age
groups; children (under 18 years of age), adults (18–64
years), and elderly (age 65 years and above), see data
selection in Flow diagrams 1–3 in the supplemental ma-
terial. We obtained SO2, PM10 (particle matter with an
aerodynamic diameter < 10 μm), and NO2 (nitrogen
dioxide) data along with meteorological data from the
Icelandic Environment Agency’s stationary air pollution
monitor located in Reykjavík (Fig. 1) for the study period
and constructed a time series of 24-mean values from
midnight to midnight.
Statistical methods
Descriptive statistics were calculated for all exposure
and outcome variables for the period before and after
the beginning of the eruption (for health data, we used
age at date of first occurrence in the data) (see Table 1,
see also supplementary material, Flow diagrams 1–3).
Correlations of the exposure variables can be found in
the supplement (Table S1). We use the t-tests to assess
as whether there was a statistically significant difference
in concentrations of relevant pollutants and the number
of daily health outcome events before, and during the
eruption (Table 1 and Table 2).
In the regression analysis of the daily number out-
comes during the whole study period, SO2 exposure was
given as either a) a continuous variable, or b) an indica-
tor value of the 24-h SO2 concentration exceeding the
air quality guideline value (125 μg/m3) [2]. We fitted dis-
tributed lag non-linear models (DNLM) to the data [30].
to identify the delay in days (lag days) from exposure to
the observed health outcomes (Supplemental Fig. S2)
and concentration response (Supplemental Fig. S3 and
Fig. S4). We estimated the effects of SO2 exposure on
Fig. 1 The Icelandic capital region, national location (black box) and eruption site indicated on the inset map (creative commons/google)
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the outcome by fitting generalized additive models
(GAM) [31].
Yt  Quasipoisson μtð Þ log μt
¼ αþ β1SO2t þ β2PM10 þ β3NO2
þ β5RelativeHumidity þ β6Idow þ β7Strike
þ β8Yt − 1 þ s1 Temperatureð Þ
þ s2 Day in the time seriesð Þ
þ s3 Day of the year; bs ¼ “cc”ð Þ
Where Yt denotes the daily number of health events,
β1 denotes the log relative rate of events associated with
a 10 μg/m3 increase in SO2 at lag 0–2. Furthermore, the
results are adjusted for co-pollutants and weather (PM10,
NO2, and relative humidity) at the same lag intervals as
the main exposure. Idow is an indicator for day of week
and odd holidays, and Strike is an indicator of strike
days (used only in analysis of the hospital and primary
care data, to indicate days where medical doctors went
on strike as part of a labor conflict, which coincided with
some high SO2 days (See Table S1 for a total list of
strike days, and Fig. 1). Several methods of addressing
this issue were tested: no adjustment, excluding strike
days, or adjusting for the indicator. The latter was found
to yield models with a better fit and was used where ap-
propriate. We used an autoregressive term (adjusting for
the outcome at lag 1) to improve the autocorrelation of
the model residuals [32]. The terms s1(Temperature)
and s2(day in the time series) are smoothing functions
which allow for non-linearity). The term s3(day of the
year, bs = “cc”) is a b-spline with a penalized cyclical
cubic (a spline whose ends match up, and is thus suit-
able for modeling annual fluctuations) term day of year
designed to control for seasonal trend [33]. Results from







Pollutant Mean (SD) Range Days with missing data Mean (SD) Range Days with missing data p*
SO2 1.4 (1.1) 0.0–20.6 20 35.7 (71.2) 1.3–418.0 0 < 0.001
PM10 20.3 (18.2) 3.8–315.4 19 17.8 (9.1) 5.7–71.5 13 0.010
NO2 15.8 (11.3) 0.0–75.9 54 12.0 (8.2) 0.4–41.0 0 < 0.001
*from a t-test of means. SD Standard deviation
Table 2 Demographic characteristics of the study population and daily number of individuals who were dispensed anti-asthma
medication (AMD) or utilized health services for respiratory disease before and during the Holuhraun eruption
Before eruption During eruption
n % Events per day, mean (%) Range n % Events per day, mean (%) Range P*
Anti-asthma medication dispensings (AMD)
All 45,473 100% 129.4 (100%) 5–715 11,094 100% 158.4 (100%) 22–301 < 0.001
Female sex n, %) 25,608 56.3% 75.1 (41.8) 2–430 6552 59.1% 93.2 (45.7%) 13–185 < 0.001
Under 18 years of age 14,144 31.1% 28.3 (21.9%) 0–139 2415 21.8% 33.2 (20.9%) 8–68 < 0.001
18–64 years of age 24,117 53.0% 60.7 (46.9%) 3–386 5623 59.7% 75.2 (47.4%) 5–149 < 0.001
65 years and older 7212 15.9% 40.4 (31.2%) 0–202 3056 27.5% 50.1 (31.6%) 0–105 < 0.001
Primary care center MD visits (PCMD)
All 106,528 100% 142.2 (100%) 17–325 15,806 100% 144.8 (100%) 41–259 0.6531
Female sex n, %) 59,429 55.7% 84.6 (59.5%) 9–180 9547 60.4% 87.9 (60.7%) 22–165 0.343
Under 18 years of age 31,240 29.3% 39.2 (27.6%) 3–136 4140 26.2% 38.0 (26.3%) 13–75 0.4019
18–64 years of age 64,840 60.9% 85.9 (60.4%) 12–191 9839 62.2% 89.7 (61.9%) 24–161 0.2951
65 years and older 10,448 9.8% 17.1 (12.0%) 0–48 1827 11.6% 17.1 (11.8%) 0–42 0.9877
Hospital emergency department visits (HED)
All 19,541 100% 18.3 (100%) 1–45 1932 100% 17.5 (100%) 4–34 0.176
Female sex n, %) 9733 49.8% 9.2 (50.5%) 0–29 1000 51.8% 9.0 (51.6%) 2–18 0.527
Under 18 years of age 6811 34.9% 5.7 (30.9%) 0–24 638 33.0% 9.0 (51.6) 0–16 0.640
18–64 years of age 8258 42.3% 7.0 (38.2%) 0–24 758 39.2% 5.5 (31.6%) 1–14 0.269
65 years and older 4472 22.9% 5.7 (31.0%) 0–19 536 27.7% 6.7 (38.0%) 0–13 0.198
*from a t-test of means
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models with no adjustment for other pollutants (Partially
adjusted models) are also presented. Quasipoisson distri-
bution was assumed for all outcomes. All analysis was
performed in R Studio [34].
Subgroup analysis
We present results from stratified analyses of categories
of anti-asthma drugs; 1) adrenergic inhalants (R03A), a
large proportion of which are short-acting beta agonists,
and 2) other inhalant drugs (R03B), mainly glucocorti-
coids and anticholinergenics. For PCMD and HED visits,
we present results stratified for 1) infectious diseases
including acute upper respiratory infections (World Health
Organisation International Classification of Disease (ICD)
codes J00-J06), influenza and pneumonia (J09-J18), and
other acute lower respiratory infections (J20-J22), and 2)
obstructive respiratory disease, including chronic obstruct-
ive pulmonary disease, COPD, and asthma (J44 and 45).
Age-stratified results are also presented.
Sensitivity analysis
To explore the robustness of the analysis, we analysed
the association between all respiratory PCC contacts in-
cluding phone calls, consultations, and “other” because
PCMD visits are subject to availability. To estimate the
total impact on the health care systems from increased
population morbidity we also analysed all PCC contacts
including recurring PCC contacts within 14 days. For
HED visits, we performed a sensitivity analysis including
only individuals who were admitted for in-patient care
(Table S3). Additionally, we performed sensitivity
analysis on different lags of SO2 for HED admissions, as
our exploratory analysis revealed lag-specific effects for
different age-categories (Fig. S2c-d, Table S3). In sensi-
tivity analysis of the exposure (Table S4), we wished to
exclude the possibility of our results being entirely due
to official advice encouraging individuals with respira-
tory diseases to have sufficient medicine at hand. This
was broadcast to the public on days with forecasts of
high SO2 and it was speculated that some SO2-associ-
ated increases in AMD could be due to compliance with
this advice. As AMD is most often dispensed in larger
quantities, a compliance effect would present itself as
decreased effect estimates of SO2 after the first days or
week of warnings as regular users have filled their
supplies. Thus, present results from analyses where we
1) excluded the first day, then 2) the first week, from the
time series (Table S4). To eliminate any confounding
effect of air pollution from other volcanic eruptions
((Eyjafjallajökull 2010 and Grímsvötn 2011) that im-
pacted air quality during the study period (Daily mean
of key air pollutants and events are indicated in Fig. S1)
[35] we reanalysed AMD, PCMD and HED excluding
the years 2010 and 2011 (Table S4). Also, we performed
analyses allowing for non-linearity of both lag structure,
and concentration of SO2 and present those results in
the supplement (Fig. S2 and Fig. S3). Furthermore, we
investigated lag-responses of sub-categories of respira-
tory disease (Fig. S4) and effects of longer lags (Fig. S5).
Results
The daily mean SO2 concentrations in Iceland’s capital
area were low or moderate until the Holuhraun eruption
began 30 August 2014. After the eruption began, 24-h
SO2 concentrations surpassed the air quality guideline
limit of 125 μg/m3 on ten days. Both mean and median
concentrations were significantly higher than before the
eruption; mean 35.7 μg/m3 (SD 71.2) vs mean 1.4 μg/m3
(SD 1.1) (Table 1, see also Fig. 2 and Fig. S1), and the
correlations between air pollutants were altered substan-
tially after the eruption (Table S1).
Before the eruption, an average of 129.4 individuals
per day were registered purchasing (=were dispensed)
AMD. There were 56.3% females and the mean age was
35.7 (SD 22.9) years. In primary care, the most common
form of contact was GP visits (61%) followed by phone
calls (33%), the daily mean number of individuals with
an MD visits in primary care (PCMD) for respiratory
disease was 142.2, the mean age was 32.8 (SD 22.5) years
and 60.9% were women. In HED, the daily mean number
of individual visits for respiratory health outcomes were
18.3, the mean age was 36.3 years (SD 29.4) and 49.8%
were women. After the eruption began, 158.4 individuals
per day were dispensed AMD, the mean age was 44.5
(SD 26.3) years. 144.8 individuals per day visited an MD
in primary care for respiratory disease, the mean age was
35.0 years (SD 26.6), 60.4% were women. In HED, 17.5
individuals attended for respiratory disease, the individ-
uals had a mean age of 39.4 years (SD 30.5) and 51.8%
were women (Table 2). Comparing the daily number
of events, only mean daily number of individuals with
AMD was significantly increased compared with the
reference period (129.4 vs 158.4, p < 0.001). Restricting
this analysis to only the time of the year where the
eruption was ongoing (using September to December
in the years 2012 and 2013 where there were no vol-
canic eruptions) we found that AMD was significantly
increased 138.2 vs 158.4, p = 0.0035). Neither total
nor age categories of HED and PCMD MD visits
were significantly higher or lower during the eruption
period as a whole compared to the period before
(Table 2, Fig. 2).
We found that for AMD, the overall time trend adjust-
ment without fixed degrees of freedom showed signs -of
overfitting and so, comparing the model fits (R2 and
explained deviance), 4 degrees of freedom was selected
as the optimal value for the time trend spline in analyses
of AMD. For PCMD and HED, the degrees of freedom
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Fig. 2 Respiratory health outcomes during the exposed period July to December 2014 (solid lines) and the unexposed previous years 2010–2013 (broken
lines) for Capital area anti-asthma medication dispensing (top), primary care MD visits (middle) and hospital emergency department visits (bottom) for
respiratory diseases as 7-day running means (right side axis). SO2 concentration (3-day running means) in grey (unit on left side axis), black vertical, broken
line mark the eruption date, grey vertical broken line marks day of first nation-wide SO2 warning. Grey shaded areas indicate MD strike in PCC and HED
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were not fixed. After inspecting the residuals for signs of
drift, we were confident that the time trends adjust for
the population increase during the study period.
In both partially (model 1) and fully adjusted (model
2) models, SO2 was associated with increased number of
AMD (model 2) by 0.99% (95% CI 0.39–1.58%) per
10 μg/m3 SO2. High SO2–days, with concentrations
exceeding the air quality guideline of 125 μg/m3 were
associated with a statistically significant increase in
AMD by 10.9% (95% CI 2.1–19.6%) at lag 0–2 (Table 3).
For PCMD and HED, the strike indicator for days where
MDs were on strike was associated with fewer outcome
events (as fewer MDs were working). The inclusion of
the strike indicator variable improved the model fit and
was an effect modifier of SO2, increasing the effect esti-
mates, and thus it was added to the following PCMD
and HED models. In primary care, SO2 was associated
by an increase in PCMD visits by 1.26% (95% CI 0.72–
1.80%) per 10 μg/m3 SO2 at lag 0–2. For PCMD, expos-
ure to SO2 over 125 μg/m
3 was associated with increases
by 17.2% (95% CI 10.0–24.4%) at lag 0–2. For HED
visits, only adjusted results (model 2) of continuous SO2
exposure at lag 0–2 yielded significant associations asso-
ciated with increase (Fig. S2d) in total HED by 1.02%
(95% CI 0.02–2.03%) per 10 μg/m3. There were no statis-
tically significant associations between high SO2 days
and total HED (Table 3). The effect estimates from the
partially adjusted models (model 1) were within the
confidence intervals of the model 2 fully adjusted results
(~ 10 percentage point change), except for HED visits
which increased from 0.83% (95% CI − 0.12 – 1.78%) in
the unadjusted model 1 to 1.02% (95% CI 0.02–2.03%)
per 10 μg/m3 SO2 in model 2 (Table 3). Fully adjusted
model results are presented from here.
Table 3 Percent excess risk associated with daily SO2 exposure at lag 0–2 (for exposure as a continuous variable, left, and as an
indicator for days with pollution levels above the air quality guideline value, right) and respiratory health outcomes in the capital
area of Iceland
SO2 (per 10 μg/m
3) SO2 levels > 125 μg/m
3
% 95% CI % 95% CI
Asthma medication (AMD)
Model 1 0.89% 0.29% 1.49% 10.5% 1.8% 20.0%
Model 2 0.99% 0.39% 1.58% 10.9% 2.1% 19.6%
Primary care MD visits (PCMD)
Model 1 1.18% 0.68% 1.69% 16.9% 9.2% 25.0%
Model 2 1.26% 0.72% 1.80% 17.2% 10.0% 24.4%
Hospital Emergency Department (HED)
Model 1 0.83% -0.12% 1.78% 11.7% −1.4% 26.7%
Model 2 1.02% 0.02% 2.03% 9.4% −3.8% 22.6%
Model 1: Adjusted for season, time trend, day of week, odd holidays, the outcome at lag 1, temperature, and relative humidity. n = 1606
Model 2: Adjusted for season, time trend, day of week, odd holidays, the outcome at lag 1, temperature, relative humidity, NO2, PM10 at the same lags as
SO2. n = 1529
Table 4 Percent excess risk associated with SO2 exposure at lag 0–2 (both for exposure as a continuous variable and for days with
pollution levels above the air quality guideline value) and changes in respiratory health in diagnosis subcategories in primary care
and hospital emergency departments in the capital area of Iceland
Mean (SD) SO2 (per 10 μg/m
3)a SO2 levels > 125 SO2 μg/m
3
% 95% CI % 95% CI
Anti-asthma medication
Short-acting β-agonist (R03A) 88 (47.2) 1.09% 0.49% 1.70% 13.7% 4.5% 23.7%
Long-acting (R03B) 38.7 (21.4) 0.74% −0.03% 1.52% 8.7% −2.2% 20.7%
Primary care MD visits (PCMD)
Respiratory infections (J0-J2) 108.6 (46.2) 1.12 0.54% 1.71% 15.8% 7.2% 25.1%
Asthma and COPD (J44–45) 15.6 (9.6) 2.08% 1.13% 3.04% 28.4% 12.8% 46.2%
Hospital emergency department visits (HED)
Respiratory infections (J0-J2) 9.3 (4.3) 1.09% −0.22% 2.41% 7.9% −60.9% 27.8%
Asthma and COPD (J44–45) 4.3 (2.7) 0.95% −0.99% 2.93% 3.3% −19.8% 33.2%
aAdjusted for season (spline), time trend (spline), day of week, odd holidays 1, temperature (spline), relative humidity, NO2, PM10 at the same lags as SO2, and the
outcome at lag
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In subgroup analysis (Table 4), the dispensing of short
acting bronchodilator medication was associated with
SO2 exposure by 1.09% (95% CI 0.49–1.70%) per 10 μg/
m3 SO2, and 13.7% (95% CI 4.5–23.7%) after high SO2
days. SO2 exposure was not significantly associated with
dispensing of long-acting corticosteroid medication. SO2
exposure was associated with increased PCMD visits for
respiratory infection diagnoses by 1.12% (95% CI 0.54–
1.71%) and obstructive pulmonary disease by 2.08% (95%
CI 1.13–3.04%) per 10 μg/m3 at lag 0–2. and PCMD
visits for %). Following high SO2 days, the estimated in-
crease in PCMD visits were 15.8% (95% CI 7.2–25.1%)
and 28.4% (95% CI 12.8–46.2%) for respiratory infections
and obstructive disease, respectively. For HED visits,
SO2 exposure was not associated with significant in-
creases in visits due to respiratory infections or asthma
or COPD although all estimates were numerically indi-
cative of a positive effect (Table 4, Fig. S4).
In analysis stratified by age, the estimated association
between SO2 and AMD exposure at lag 0–2 were highest
in children, and lower in elderly, however, all confidence
intervals overlapped in both partially and fully adjusted
models (Table 5). In PCMD, the effect estimates were
highest in adults, and was not statistically significant in
elderly.
Changing the outcome to include all primary care
contacts (also phone calls) and further including the
recurring contacts for the same diagnostic category
within 14 days only marginally alter the results (17.2% vs
17.4% vs 20.3%) for high SO2 levels (Table S3).
Considering effects on HED of SO2 exposure at lag 2–
4, the effect estimated in children increased numerically
from 1.22% (95% CI -0.62 – 3.10%) to 2.21% (95% CI
0.30–3.97%) however, the confidence intervals over-
lapped and statistical power was low (Table S3).
Confining the analysis of HED to those wwo were
admitted, there were no associations between SO2
exposure at lag0–2, but admission in children were in-
creased at lag 2–4 by 6.6% per 10 μg/m3 SO2 (Table S3).
Excluding the first day in a series of high SO2 days
from the exposure variable yielded very similar estimated
effects of SO2 exposure to the main analysis for AMD,
but slightly lower for PCMD (Table S4). Excluding the
whole week after the first high SO2 concentration day,
effect estimates for PCMD visits were higher in elderly
compared with the main analysis (Table S4). Excluding
the years 2010 and 2011 yielded statistically significant
effect estimates for total AMD and PCMD, but only
HED in elderly was significantly increased (Table S4). In
the analysis of HED admissions rather than all HED
visits, all effect estimates were positive, but there were
no significant associations between SO2 and HED at lag
0–2. When increasing the lag-period to 20 days we
observed a second increase in PCMD at lag 16 after the
initial SO2 exposure, and at lag 11–13 for HED in young
people and adults (Fig. S4).
Discussion
Although SO2 pollution levels were overall higher after
the Holuhraun eruption began (Table 1), a crude
comparison of respiratory health care utilisation in
Iceland’s capital area before and after the beginning of
the Holuhraun eruption (Table 2) showed that only
AMD increased significantly compared to the corre-
sponding months in previous years, as well as com-
pared to the total control period.. However, in time
Table 5 Percent excess risk in age-specific respiratory health outcomes associated with SO2 exposure at lag 0–2 (both for exposure
as a continuous variable and for days with pollution levels above the air quality guideline value)
SO2 (per 10 μg/m
3) SO2 levels > 125 μg/m
3
% 95% CI % 95% CI
Anti-asthma medication (AMD)
Children 0–17 1.48% 0.61% 2.35% 20.2% 7.8% 32.6%
Adults 18–65 0.86% 0.20% 1.53% 11.3% 1.8% 20.9%
Elderly > 65 0.90% 0.14% 1.67% 9.8% −1.4% 20.9%
Primary care MD visits (PCMD)
Children 0–17 1.24% 0.40% 2.08% 14.2% 3.0% 25.5%
Adults 18–65 1.21% 0.63% 1.79% 18.5% 10.6% 26.3%
Elderly > 65 1.11% 0.14% 2.09% 11.8% −2.0% 25.6%
Hospital Emergency Department (HED)
Children 0–17 1.22% −0.62% 3.10% 7.0% −18.7% 32.7%
Adults 18–65 0.52% − 0.99% 2.06% 0.0% −20.7% 20.7%
Elderly > 65 1.01% −0.62% 2.66% 19.7% −1.8% 41.2%
All results are adjusted for season, time, day of week, odd holidays, the outcome at lag1, and MD strike for PCC and HED, relative humidity, temperature, PM10,
and NO2. n = 1788
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series regression analysis (Table 3), SO2 concentrations
were associated with increased AMD, PCMD and HED
for respiratory causes at lag 0–2. Analysing the association
with SO2 levels which exceeded the 24-h health limit
(125 μg/m3) to quantify the risk associated with high levels
yielded similar results, and spline plots suggest a linear
dose-response curve (Table 3, see also Fig. S3). Stratifying
AMD into subgroups, only dispensing of short-acting
medications were significantly increased, indicating that
dispensing of short-acting drugs are a more sensitive indi-
cator of an immediate need for symptom relief, although
the use of short-acting drugs are not specific to asthma
disease (Table 4). In PCMD we found that PCMD for
respiratory infections and obstructive lung disease were
increased and the increase in obstructive lung disease
suggested that individuals with this diagnosis were
increasingly in need of care following SO2 exposure
(Table 4). For COPD diagnoses in HED, our results indi-
cated a positive association, but it was lower than for
PCMD, and the results did not reach statistical significance.
Stratifying by age-categories, the results indicated that
for AMD, we observed with highest risk estimates with
SO2 exposure in individuals under 18, for PCMD, adults
had highest risk, and for HED the highest risk was in indi-
viduals 65 and older (Table 5), except for lag2–4, where it
was higher in individuals under 18 (Table S3). However,
the confidence intervals overlapped, and the association
between SO2 and HED in elderly was not significant after
adjusting for other pollutants than SO2 (Table 5).
Exploring definitions of outcomes in primary care in
sensitivity analyses, the tendency towards increasing
effect estimates in elderly in analyses of all contacts and
recurring contacts (Table S3) rather than non-recurring
MD visits suggests that the care burden is higher in this
group, but the confidence intervals overlapped with
those in the main analysis (Table 5). In HED admissions,
a high effect estimate was seen for both continuous SO2
and high SO2 days in children at lag2–4, but the confi-
dence intervals were wide (Table S3).
In the regression analysis, the choice of lags were
based on inspection of lag structures generated by lag-
splines (Fig. S2). For AMD and PCMD visits, the ob-
served effects of SO2 exposure occurred during the same
day and up to 2 days after a peak in SO2 concentration
(Figs. S2a-b). However, for HED visits in elderly, the
observed effects occurred already at lag 0 (Fig. S2c-d). A
possible explanation for this is that primary care is the
first point of contact for most individuals and hospital
care is sought only after other care options have been
exhausted, but for elderly, hospital care is sought imme-
diately, possibly due to a more severe presentation of
symptoms or complications due to underlying diseases,
as illustrated by a significant association between SO2
and HED in elderly before adjusting for other pollutants
at lag0–2 (Table S3), and significant association only
with HED in children at lag 2–4 (Table S3). Unfortu-
nately, we did not have access to information about
comorbidities and were unable to adjust for this.
In the sensitivity analysis to investigate the influence of
compliance with official advice, the effect of initial warn-
ings of volcanic gas exposure appeared to be limited, as
excluding the first day or week of high SO2 yielded similar
estimates for AMD and PCC visits as the main analysis, al-
though there was some loss of statistical power (Table S4).
We speculate that since the increases in AMD and PCC
persisted after the first exposed day and weeks, this indi-
cates that the observed increases in health care utilisation
reflect actual increased respiratory morbidities rather than
merely adherence to official advice (Supplemental Table
S4). Excluding the years 2010 and 2011 from the analysis
to exclude effects of volcanic ash from Eyjafjallajökull and
Grímsvötn yielded results within confidence intervals of
our main analysis (Table S4). Investigating longer lags, we
observed statistically significant increases in total PCMD
and HED visits in young and adults at more than 15 days
delay, but in both cases, these follow periods of decreases
in outcomes, and are challenging to interpret (Fig. S5).
Although it has been suspected that the complex mix-
ture of a volcanic plume [7] could have different health
effects than merely SO2, we found that our results were
consistent with concentration-response functions found
in studies from urban settings; e.g. respiratory mortality
rates were estimated to increase by 2.4% per 27 μg/m3
SO2 (Li et al. 2017), corresponding to a point estimate of
0.88% per 10 μg/m3 SO2, lower, but within the confi-
dence interval of the estimated increases of HED found
in our study, namely 1.02% (95% CI 0.02–2.03%) per
10 μg/m3. In previous studies of SO2 exposure during
volcanic eruptions, the SO2 concentration on Miyake-
jima Island increased after Mount Oyama erupted in
2000 meaning that residents and aid workers returning
to the island from 2005 and onwards were exposed.
Children living on the island who were exposed to daily
mean concentration of 125 μg/m3 SO2, had increased
rates of wheezing [36]. In follow-up studies, permanent
residents of Miyakejima Island (n = 168) who lived in
areas with high SO2 exposure reported increased rates of
cough and wheeze [13], both symptoms of asthma. None
of the studies of people exposed at Miyakejima Island
found adverse effects on lung function [12, 14, 36].
Regarding individual susceptibility, we observed the
highest effect estimates for PCMD visits for asthma
and COPD (Table 4), indicating that individuals with
these diseases are at increased risk, which is. Hyper-
responsiveness to SO2 has previously been reported as
common (20–25%) in individuals with positive asthma test
(methacholine test), indicating that they may be particu-
larly vulnerable to severe SO2 exposure [4]. Non-smokers
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have previously been reported as being at risk of symp-
toms after volcanic SO2 exposure [11], but unfortunately,
smoking status was not available in our data.
Respiratory infections were increased in our study and
similarly rates of cough and acute pharyngitis diagnosed
at a clinic in SO2 –exposed communities near The
Kilauea Volcano in Hawaii increased after a eruption
activity increased in 2008 [18]. Respiratory infection
diagnoses in PCMD were statistically significantly associ-
ated with SO2, a similar association has previously been
reported for hospital visits for upper respiratory tract
infections [37]. Volcanic eruptions have been associated
with altered rates of other health outcomes such as
accidents and mortality [38], but these fell outside the
scope of this study.
Our study employs a time series design were individ-
ual level risk factors are not time-dependent and thus
should not confound the association between short term
exposure to air SO2 and health outcomes, leaving bias
due to unmeasured confounders, seasonal variation, and
other intermittent exposures as main concerns. Previous
studies of health effects of air pollution in Iceland have
yielded lower effect estimates of daily air pollution on
morbidity than the current study [39, 40], other air
pollution exposure types are thus not likely to bias
the results. This includes H2S, which has a low cor-
relation (< 0.1) with the exposure of interest during
the study period (data not shown). During the refer-
ence period, there were two ash-rich volcanic erup-
tions, in Eyjafjallajökull 2010 and Grímsvötn 2011.
While ash from Eyjafjallajökull had local respiratory
health effects [24] and there may have been adverse
health effects in the capital area [40], neither eruption
had significant SO2 emissions and sensitivity analysis
excluding this period yielded results within the confidence
interval of the main study results (Supplemental Table S5).
The exposed period October and November of 2014 did
not coincide with any viral respiratory illnesses (e.g. influ-
enza and RS-virus) epidemic [41, 42], but it did coincide
with the MD labour conflict which resulted in lower PCMD
and HED attendance during those days. Hence, results
from the analysis comparing the eruption period with the
time before may have underestimated of true effect of the
SO2 from the eruption.
SO2, PM10 and NO2 data was missing for a number of
days which were excluded from the analysis. As the
volcanic plume effectively changed the chemical com-
position of the atmosphere during the eruption period
(Supplemental Tables S1a-b), the correlations of SO2
with other air pollutants were altered after the eruption.
Results that were adjusted for other pollutants were
nearly identical to the main analysis (Table 3), indicating
that the effect of the very high concentrations of SO2
was unambiguous.
It is a strength of the current study that health data
were collected prospectively from population-wide
registers, which minimizes the risk of information bias
from individuals knowing their exposure status. Al-
though the exposure would have been known to the
public for at least part of the exposed period but we
attempt to address this source of bias in the unadjusted
analysis and found only moderate changes to the results
(Table S3). As a study outcome, we use dispensing of
asthma-medication, a novel and more sensitive proxy for
respiratory health in a population [28] than primary care
attendance and hospital visits. It targets individuals who
are already sensitive to poor air quality [26, 29] who in
most cases have contact with the health care system. A
limitation with register-data is that the data are not
collected for research purposes and diagnoses given in
the health care system could be biased and lead to over-
estimation as medical professionals assume respiratory
outcomes to be more likely during the eruption. How-
ever, as the estimated effect are similar across all respira-
tory outcomes we conclude that this source of bias is
not likely to explain our findings. By defining exposure
status based on residential postcode we make several as-
sumptions, firstly, that the whole area is equally exposed,
and secondly, that the study participants are physically
near their homes. However, these sources of bias would
result in wider confidence intervals or bias the results
toward the null. Reykjavík and the Icelandic capital area
was exposed to SO2 concentrations above 125 μg/m
3
during a total of ten days which occurred mostly during
October and November 2014. This limits the statistical
power of the study and our options for further analysis,
as does the fact that our study period did not extend
until after the eruption, meaning that we cannot fully
assess the complete impact of the health impact from
the eruption on the population from our results.
Conclusions
In conclusion, this comprehensive study with prospect-
ively collected data on volcanic SO2 air pollution expos-
ure and respiratory health outcomes, is the first to firmly
establish an association between spikes of high SO2 con-
centrations and respiratory outcomes in the general
population, and specifically in individuals with prevalent
respiratory disease. These findings emphasize the need
for attention from authorities and susceptible individuals
during times of volcanic eruptions.
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